BCYC
Price:
$14.69
Market Cap:
$1.01B
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a...[Read more]
Industry
Biotechnology
IPO Date
2019-05-23
Stock Exchange
NASDAQ
Ticker
BCYC
According to Bicycle Therapeutics plc’s latest financial reports and current stock price. The company's current PE Ratio is -4.48. This represents a change of -35.83% compared to the average of -6.98 of the last 4 quarters.
The mean historical PE Ratio of Bicycle Therapeutics plc over the last ten years is -9.64. The current -4.48 PE Ratio has changed 4.55% with respect to the historical average. Over the past ten years (40 quarters), BCYC's PE Ratio was at its highest in in the June 2019 quarter at -1.77. The PE Ratio was at its lowest in in the December 2021 quarter at -24.29.
Average
-9.64
Median
-7.55
Minimum
-22.83
Maximum
-3.40
Discovering the peaks and valleys of Bicycle Therapeutics plc PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 238.87%
Maximum Annual PE Ratio = -3.40
Minimum Annual Increase = -65.88%
Minimum Annual PE Ratio = -22.83
Year | PE Ratio | Change |
---|---|---|
2023 | -3.56 | -54.27% |
2022 | -7.79 | -65.88% |
2021 | -22.83 | 238.87% |
2020 | -6.74 | 97.98% |
2019 | -3.40 | -53.40% |
2018 | -7.30 | -25.57% |
2017 | -9.81 | -37.58% |
The current PE Ratio of Bicycle Therapeutics plc (BCYC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-11.39
5-year avg
-8.86
10-year avg
-9.64
Bicycle Therapeutics plc’s PE Ratio is greater than IDEAYA Biosciences, Inc. (-12.24), less than AnaptysBio, Inc. (-2.42), greater than MeiraGTx Holdings plc (-5.01), less than Keros Therapeutics, Inc. (-3.32), less than Homology Medicines, Inc. (-0.01), less than Tenaya Therapeutics, Inc. (-1.22), less than IGM Biosciences, Inc. (-1.77), greater than Monte Rosa Therapeutics, Inc. (-4.84), greater than Stoke Therapeutics, Inc. (-6.05), greater than Merus N.V. (-11.84), less than Inhibrx Biosciences, Inc. (0.14), greater than immatics biotechnologies GmbH (-11.79), less than Seer, Inc. (-1.64), greater than ORIC Pharmaceuticals, Inc. (-4.82), greater than Anebulo Pharmaceuticals, Inc. (-5.30), greater than Cullinan Oncology, Inc. (-4.99), less than C4 Therapeutics, Inc. (-2.55), less than Adagene Inc. (-2.67), less than Acrivon Therapeutics, Inc. Common Stock (-3.08), less than Mineralys Therapeutics, Inc. (-4.16),
Company | PE Ratio | Market cap |
---|---|---|
-12.24 | $2.19B | |
-2.42 | $422.65M | |
-5.01 | $482.21M | |
-3.32 | $676.88M | |
-0.01 | $3.02M | |
-1.22 | $131.51M | |
-1.77 | $380.57M | |
-4.84 | $433.13M | |
-6.05 | $599.59M | |
-11.84 | $2.90B | |
0.14 | $209.76M | |
-11.79 | $827.74M | |
-1.64 | $130.32M | |
-4.82 | $577.94M | |
-5.30 | $42.01M | |
-4.99 | $714.45M | |
-2.55 | $273.18M | |
-2.67 | $85.89M | |
-3.08 | $193.98M | |
-4.16 | $637.04M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bicycle Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Bicycle Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Bicycle Therapeutics plc's PE Ratio?
How is the PE Ratio calculated for Bicycle Therapeutics plc (BCYC)?
What is the highest PE Ratio for Bicycle Therapeutics plc (BCYC)?
What is the 3-year average PE Ratio for Bicycle Therapeutics plc (BCYC)?
What is the 5-year average PE Ratio for Bicycle Therapeutics plc (BCYC)?
How does the current PE Ratio for Bicycle Therapeutics plc (BCYC) compare to its historical average?